Kidney Cancer Weekly

March 09, 2026

Videos

Peer-to-Peer Clinical Conversations

Real-World Experience With the Expanded Access Program for 89Zr-Girentuximab PET in Small Renal Masses - R. Jonathan Henderson

Jonathan Henderson

Zachary Klaassen hosts Jonathan Henderson to discuss his experience with the Expanded Access Program for [89Zr]Zr-girentuximab PET imaging for small renal masses.

View

Validation Study of the GRANT Score for Papillary Renal Cell Carcinoma - Michele Maffezzoli

Pedro Barata speaks with Michele Maffezzoli to discuss his validation of the GRANT score for papillary renal cell carcinoma.

View

Beyond the Abstracts

Peritoneal Recurrence Following Nephrectomy for Localized Renal Cancer: A Multicenter European Real-World Analysis of Incidence, Pattern and Treatment (PEMET Study-UroCCR 124) - Beyond the Abstract

Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study - Beyond the Abstract

Conference Coverage

ASCO GU 2026: First Results of a Dose-Escalation Study Evaluating CBM588 with Nivolumab + Ipilimumab in Metastatic RCC

ASCO GU 2026: Adjuvant Pembrolizumab in Non-Clear Cell RCC After Nephrectomy: An International Multicenter Study

ASCO GU 2026: Response of Venous Tumor Thrombi in RCC to Immune Checkpoint Inhibitor Therapy: A Multicenter Retrospective Cohort Study

ASCO GU 2026: Geographic Disparities in the Availability of RCC Clinical Trials in the US

ASCO GU 2026: Head to Head Comparison of Pembrolizumab + Axitinib Versus Pembrolizumab + Lenvatinib in Metastatic RCC: Real World Data from the Canadian Kidney Cancer Information System Database

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Survival outcomes after surgical treatment for non-clear cell renal cell carcinoma with tumor thrombus extension: a population-based cohort study.

Node Positive Resected Renal Cell Carcinoma Portends a Poor Prognosis: Results From the Canadian Kidney Cancer Collaboration.

A systematic review comparing sex-specific outcomes of prospective clinical trials and subsequent real-world data focusing on systemic treatment options for renal cell cancer.

Ablation and Surgery Show Comparable Long-term Outcomes for T1a Renal Cell Carcinoma: A Danish Nationwide Registry Study.

Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma.

Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.

Preoperative predictors of adverse pathology and recurrence-free survival for patients with renal masses.

Renal Cell Carcinoma: Characteristics of Patients, Treatment, and Disease Progression Based on Real-World Data From a Cancer Center in Medellín, Colombia.

KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model.

Prediction Models for Shared Decision-making by Patients with Localised Renal Masses: A Systematic Review and a Survey of Patient and Clinician Priorities.

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login